Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a single centre Phase 1 trial of the PI3K inhibitor BKM120, given concomitantly with palliative radiotherapy for the treatment of Non-Small Cell Lung Cancer (NSCLC).

A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.

To determine the safety, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 when administered concomitantly with thoracic radiotherapy in patients with metastatic NSCLC.

Primary Objective:

  • To determine the safety, dose-limiting toxicity (DLT) and MTD of BKM120 when administered concomitantly with thoracic radiotherapy in patients with incurable NSCLC

Secondary Objective:

  • To investigate whether BKM120 alters tumour hypoxia and perfusion

Exploratory Objectives:

  • To evaluate Akt phosphorylation as a predictive marker of response to BKM120
  • To investigate potential biomarkers that correlate with response to BKM120

Our team

  • Sarah Pearson

    OCTO Trial Management Director